Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
J Public Health (Oxf) ; 42(1): 141-148, 2020 02 28.
Article in English | MEDLINE | ID: mdl-30715426

ABSTRACT

OBJECTIVE: To describe the prevalence of Spanish workers with Metabolic Syndrome (MetS) and those at risk of developing MetS in 2015. METHODS: Cross-sectional study of workers (n = 15 614). We used a modified definition of the NCEP:ATPIII criteria for MetS (we used body mass index (BMI) above 28.8 kg/m2 instead of the waist circumference criterion). We calculated the prevalence of MetS (having at least three components) and of being at risk of MetS (having one or two components). We calculated adjusted odds ratios (aOR) of MetS according to socio-economic and workplace characteristics. RESULTS: The proportions of workers with and at risk of MetS were 7.1 and 31.9%, respectively. The most prevalent criterion was having a BMI > 28.8 kg/m2 (24.1%) in men and cHDL < 40 mg/dl in women (12.9%). There were significant associations between MetS and men (aOR compared to women = 3.73, CI 95%: 3.19; 4.36); age (higher among oldest, aOR = 5.75, CI 95%: 4.37;7.56); and social class (higher among lower social class, aOR = 2.03, CI 95%: 1.65;2.48). CONCLUSION: Reducing any of the five MetS components, while taking into account the differences found by socio-economic and workplace characteristics, should be one priority for reducing MetS prevalence.


Subject(s)
Metabolic Syndrome , Body Mass Index , Cross-Sectional Studies , Female , Humans , Male , Metabolic Syndrome/epidemiology , Prevalence , Risk Factors , Waist Circumference
2.
Rev Esp Quimioter ; 23(4): 196-200, 2010 Dec.
Article in Spanish | MEDLINE | ID: mdl-21191558

ABSTRACT

INTRODUCTION: Lipophilic corynebacteria are part of the saprophytic skin flora and they rarely cause infection. C. macginleyi is an exception since it has been involved in conjunctivitis and other ocular surface affections. MATERIAL AND METHODS: Thirty three C. macginleyi strains were obtained from conjunctival swabs from patients with conjunctivitis symptoms. The minimum inhibitory concentration (MIC) for 7 antibiotics (penicillin, gentamycin, ciprofloxacin, tetracycline, vancomycin, rifampicin and linezolid) was tested by broth microdilution method. RESULTS: One strain was resistant to ciprofloxacin (MIC=16 mg/L) and two were resistant to tetracycline (MIC= 64 y 16 mg/L). The rest of the strains were susceptible to all the antibiotics tested. CONCLUSIONS: At the moment, C. macginleyi does not present a major problem due to the low resistance rates shown in the present and other studies. However, epidemiological surveillance of its susceptibility pattern is needed as well as an appropriate use of topical antibiotics in order to achieve a good infection control.


Subject(s)
Anti-Bacterial Agents/pharmacology , Conjunctivitis/microbiology , Corynebacterium Infections/microbiology , Corynebacterium/drug effects , Adult , Aged , Aged, 80 and over , Ciprofloxacin/pharmacology , Conjunctiva/microbiology , Conjunctivitis/drug therapy , Corynebacterium Infections/drug therapy , Drug Resistance, Bacterial , Eye Diseases/complications , Female , Humans , Male , Microbial Sensitivity Tests , Middle Aged , Tetracycline Resistance
3.
Rev. esp. quimioter ; 23(4): 196-200, dic. 2010. tab
Article in Spanish | IBECS | ID: ibc-83882

ABSTRACT

Introducción. Las corinebacterias lipofílicas forman parte de la flora saprófita de la piel y mucosas del ser humano y raramente son productoras de infección. C. macginleyi es una excepción, ya que se ha visto implicada en casos de conjuntivitis y otras afecciones oculares. Material y métodos. Se obtuvieron 33 cepas de C. macginleyi procedentes de exudados conjuntivales de pacientes con síntomas de conjuntivitis. La concentración mínima inhibitoria (CMI) para 7 antibióticos de uso oftálmico (penicilina, gentamicina, ciprofloxacino, tetraciclina, vancomicina, rifampicina y linezolid) fue probada mediante microdilución en caldo. Resultados. Sólo se detectó una cepa resistente a ciprofloxacino (CMI = 16 mg/L) y dos cepas resistentes a tetraciclina (CMI= 64 y 16 mg/L). El resto de cepas fueron sensibles a todos los antibióticos probados. Conclusiones. C. macginleyi por el momento no parece presentar un problema importante por las bajas tasas de resistencia que el microorganismo ha mostrado en éste y otros estudios, si bien es necesario la vigilancia epidemiológica de las resistencias de la bacteria así como un buen uso de los antibióticos en colirio con el objeto de realizar un tratamiento adecuado de la infección(AU)


Introduction. Lipophilic corynebacteria are part of the saprophytic skin flora and they rarely cause infection. C. macginleyi is an exception since it has been involved in conjunctivitis and other ocular surface affections. Material and methods. Thirty three C. macginleyi strains were obtained from conjunctival swabs from patients with conjunctivitis symptoms. The minimum inhibitory concentration (MIC) for 7 antibiotics (penicillin, gentamycin, ciprofloxacin, tetracycline, vancomycin, rifampicin and linezolid) was tested by broth microdilution method. Results. One strain was resistant to ciprofloxacin (MIC= 16 mg/L) and two were resistant to tetracycline (MIC= 64 y 16 mg/L). The rest of the strains were susceptible to all the antibiotics tested. Conclusions. At the moment, C. macginleyi does not present a major problem due to the low resistance rates shown in the present and other studies. However, epidemiological surveillance of its susceptibility pattern is needed as well as an appropriate use of topical antibiotics in order to achieve a good infection control(AU)


Subject(s)
Humans , Male , Female , Microbial Sensitivity Tests/methods , Sensitivity and Specificity , Corynebacterium , Corynebacterium/isolation & purification , Conjunctivitis/drug therapy , Conjunctivitis/microbiology , Conjunctivitis, Viral/drug therapy , Microbial Sensitivity Tests/trends , Penicillins/therapeutic use , Gentamicins/therapeutic use , Ciprofloxacin/therapeutic use , Tetracycline/therapeutic use , Vancomycin/therapeutic use , Rifampin/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...